# Fisher Wallace Labs (2025)

Closed: Dec. 2025

## About this raise

Fisher Wallace Labs, with a valuation of $120 million, is raising funds on DealMaker Securities. The company is building and commercializing wearable brain stimulation technology for the rapid treatment of anxiety, depression, insomnia, and other neuropsychiatric and cognitive disorders. Under temporary FDA clearance, Fisher Wallace commercialized its proof-of-concept Version 1.0 device and is on track to receive regulatory approval for the Version 2.0 technology. The business has sold over 100,000 units, has 14,000 prescribers, and has generated $40 million in revenue. The company executed a Cooperative Research and Development Agreement with the US Department of Veterans Affairs in September 2025 and expects to receive FDA clearance for anxiety treatment by May 2026. Charles Fisher founded Fisher Wallace Labs in August 2019. The current crowdfunding campaign has a minimum target of $103,505.21 and a maximum target of $2.6 million. The campaign proceeds will be used for clinical research, regulatory consulting & legal fees, manufacturing, product development, and operations.

## Investment Overview

**Invested this round:**  $188,842

### Deal Terms

#### Total Commitments

**Platform**: DealMaker Securities  
**Start Date**: 11/24/2025  
**Close Date**: 12/15/2025  
**Min. Goal**: $103,505  
**Max Goal**: $2,587,503  
**Min. Investment**: $101  
**Security Type**: Equity - Common  
**Company Stage**: Growth Stage  
**SEC Filing Type**: RegCF  
**Price Per Share**: $11.19  
**Pre-Money Valuation**: $120,000,000

### Company & Team

#### Company

**Year Founded**: 2019  
**Industry**: Fitness & Wellness  
**Tech Sector**: Medtech  
**Distribution Model**: B2B/B2C  
**Margin**: Medium  
**Capital Intensity**: High  
**Location**: Brooklyn, New York  
**Business Type**: Growth

#### Team

**Employees**: 5  
**Prior Founder Exits?**: No  
**Founder Name**: Kelly Roman  
**Title**: Co-Founder and CEO

**Founder Name**: Charles Fisher  
**Title**: Co-Founder and Chairman

## Financials

**Revenue**: 
$47.4K (FY24)  
**Monthly Burn**: $131.7K (as of FY24)  
**Runway**: 1.3 months (as of Oct '25)  
**Gross Margin**: 94% (as of FY24)

### Summary Profit and Loss Statement

|  | FY 2024 | FY 2023 |
| --- | --- | --- |
| Revenue | $47,412 | $2,019,527 |
| COGS | $3,012 | $350,736 |
| Net Income | $-1,579,900 | $-1,644,382 |

### Summary Balance Sheet

|  | FY 2024 | FY 2023 |
| --- | --- | --- |
| Cash | $41,626 | $311,160 |
| Total Assets | $154,382 | $361,017 |
| Total Liabilities | $1,537,376 | $1,436,073 |

## Company Funding & Growth

### Funding history

**Total Prior Capital Raised**: $25,550,000  
**VC Backed?**: Yes

| Offering Name | Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Fisher Wallace Labs | 07/31/2026 | DealMaker Securities | $120,500,000 | $0 | Equity - Common | Active | RegCF |
| Fisher Wallace Labs | 02/20/2026 | DealMaker Securities | $102,500,000 | $125,720 | Equity - Common | Funded | RegCF |
| Fisher Wallace Labs | 12/15/2025 | DealMaker Securities | $120,000,000 | $188,842 | Equity - Common | Funded | RegCF |
| Fisher Wallace Labs | 10/22/2025 | DealMaker Securities | $115,200,000 | $220,460 | Equity - Common | Funded | RegCF |
| Fisher Wallace Labs | 03/12/2025 | DealMaker Securities | $108,800,000 | $203,314 | Convertible Note | Funded | RegCF |